• linkedin
  • Increase Font
  • Sharebar

    Device efficacious for treating IC with Hunner’s lesions

    Lidocaine-releasing system reduces lesion number, severity, size by day 14

    Rochester, MI—A novel lidocaine-releasing intravesical system (LiRIS, Allergan) demonstrated promising efficacy and safety in a small proof-of-concept study investigating its use as a treatment for women suffering from interstitial cystitis (IC) with Hunner’s lesions, reported Kenneth M. Peters, MD, at the AUA annual meeting in San Diego.

    The two-center, phase Ib study analyzed efficacy data for seven patients who underwent cystoscopic insertion of the novel lidocaine delivery device on days 0 and 14. Evaluations of Hunner’s lesions were performed on days 14 and 28, and women were followed for 12 weeks after device removal.

    The results showed improvements in lesion number, severity, and size by day 14. Corresponding with the lesion changes, the women benefited with reductions in pain, voiding frequency, and other IC-related symptoms and problems that were sustained during the post-treatment follow-up. No significant safety concerns emerged.

    Kenneth M. Peters, MDDr. Peters“Previously, the only management options available for IC patients with Hunner’s lesions has been surgery to cauterize the lesions or injection of the lesions with a steroid. Although this study includes a very small population, we are excited about the potential of the lidocaine-releasing system for treating IC in patients with and without Hunner’s lesions. Now, we are looking forward to the results from ongoing phase II double-blind randomized trials,” said Dr. Peters, professor and chair in urology, Oakland University William Beaumont School of Medicine, Rochester, MI.

    Dr. Peters and Anthony Cantwell, MD, of Daytona Beach, FL, were the study investigators.

    The intravesical system contains 400 mg of lidocaine, and releases its load over a period of 14 days. It was previously shown to have potential benefit as a treatment for IC in a study including 16 women, of whom six had Hunner’s lesions (Sci Transl Med 2012; 4:143ra100).

    The study investigating the intravesical lidocaine delivery system in a pure Hunner’s lesion population enrolled 10 patients who had a mean age of 57 years. Eligibility criteria required a pain Numeric Rating Scale (NRS) score of 3 to 9.5, presence of at least one Hunner’s lesion at a screening cystoscopy, and at least eight daily voids.

    One patient who received only one treatment, one who expelled the device prior to day 28, and one who did not complete follow-up were excluded from the per-protocol efficacy analysis.

    Next: Improvements seen in six of seven women

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll